Ignite Creation Date:
2025-12-24 @ 5:23 PM
Ignite Modification Date:
2026-02-20 @ 5:56 PM
Study NCT ID:
NCT06542250
Status:
RECRUITING
Last Update Posted:
2025-12-15
First Post:
2024-07-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | B-cell Malignancies | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CD20 | View |
| None | CD8 | View |
| None | T cell engager | View |
| None | TCR | View |
| None | AZD5492 | View |
| None | Relapsed, Refractory | View |
| None | B-cell malignancies | View |
| None | CLL, Chronic lymphocytic leukemia | View |
| None | SLL, Small lymphocytic lymphoma | View |
| None | MCL, Mantle cell lymphoma | View |
| None | LBCL, Large B-cell lymphoma | View |
| None | FL, Follicular lymphoma | View |
| None | TITANium | View |
| None | TCE | View |